AMANDA MORDECAI: Open Payments
NPI 1336591882 · COLUMBUS, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,557 in 78 payments from 29 companies in 2025. Trend: 2023 $1,227 · 2024 $1,712 · 2025 $1,557
Food & beverage: $1,514Education: $43
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 13 | $258 |
| Merck Sharp & Dohme LLC | 8 | $177 |
| Daiichi Sankyo Inc. | 6 | $133 |
| Incyte Corporation | 4 | $87 |
| PFIZER INC. | 5 | $87 |
| Celgene Corporation | 4 | $85 |
| ABBVIE INC. | 4 | $76 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $58 |
| Gilead Sciences, Inc. | 3 | $57 |
| JAZZ PHARMACEUTICALS INC. | 2 | $52 |
Products named: KEYTRUDA, KISQALI, Enhertu, REBLOZYL, PLUVICTO, MONJUVI, Trodelvy, SCEMBLIX.
Industry payments across MS — which companies pay providers there.
